Peripheral sympathetic control during dobutamine infusion
effects of aging and heart failure
Sonia Velez-Roa, MD*,*,
Marc Renard, MD, PhD*,
Jean-Paul Degaute, MD, PhD* and
Philippe van de Borne, MD, PhD*
* Department of Cardiology, Erasme Hospital, Brussels, Belgium
View larger version (29K):
[in a new window]
|
Figure 1 Individual recordings of the effects of dobutamine infusion on heart rate (HR), mean blood pressure (MBP), and sympathetic nerve activity (MSNA). In a young control, arterial baroreceptor activation produced by marked increases in MBP with dobutamine inhibits MSNA and limits the rise in HR. In a control subject matched to the congestive heart failure (CHF) patient, dobutamine does not increase MBP, and, in the absence of arterial baroreflex activation, MSNA remains unchanged, and the chronotropic effect of dobutamine is preserved. In a CHF patient, dobutamine produces similar effects to those seen in the matched control, except that HR does not increase.
|
|
View larger version (9K):
[in a new window]
|
Figure 2 Regression analysis between changes in muscle sympathetic nerve activity (MSNA) (burst/min, left panel), heart rate (HR) (beats/min [bpm], right panel), and mean arterial blood pressure (MBP) (mm Hg) during dobutamine infusion in the control subjects; the largest increases in MBP are accompanied by the most pronounced inhibitions in MSNA as well as with the least increases in HR.
|
|
|
